Abstract
The recent successes of immunotherapy have shifted the paradigm in lung cancer treatment. Only a percentage of patients are responsive to immunotherapy, thus, it is imperative to identify factors impacting outcome. Body composition phenotypes may reflect aspects of patients’ immunology and thereby their ability to respond to immunotherapies. Therefore, our study aimed to describe the pre-treatment body composition profile of patients and explore the possible associations between these parameters and clinical outcomes in non-small-cell lung cancer (NSCLC) patients receiving first-line Pembrolizumab monotherapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
